SKB BIO

6990
440.0001.79% ( -8.000 )
Delay Closed: Nov 16, 16:08:11

Overview

SKB BIO (6990)

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of...

Open
440.400
High
441.800
Low
426.600
Prev. Close
448.000
Volume
803.94K
Turnover
350.81M
Avg Price
436.363
Bid/Ask Ratio
-41.18%
Amplitude
3.39%
52wk High
562.500
Volume Ratio
0.64
Turnover Ratio
0.45%
52wk Low
339.600
HK Mkt Cap
77.80B
Market CapHKD
105.17B
P/ETTM
604.10
P/EDynamic
117.71
P/EStatic
--
EPSTTM
0.728
EPSDynamic
3.74
EPSStatic
--
BVPS
25.71
P/B
17.12
HK Shares
176.82M
Dividend YieldTTM
--
DividendTTM
--
Shares
239.02M
Min lot size
100
Currency
HKD

SKB BIO Analyst Rating

View more

Forecast & Rating

Nov 11, 2026
Price forecast
HK$617.6040.36%
Forecast & RatingStrong buy
21analysts
  • Strong buy80.95%
  • Buy14.29%
  • Hold4.76%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Kelun-Biotech surged 6.7% to close at HKD 499 on heavy volume, driven by ASCO data showcasing sac-TMT plus pembrolizumab in first-line PD-L1-positive NSCLC published in The Lancet and Merck advancing 17 trials for its core ADC. The stock staged a V-shaped rebound after slipping to an intraday low of HKD 477.2 in morning trade, reaching HKD 499.6 in late afternoon. Q4 revenue jumped 110% YoY to HKD 615.8M while net loss narrowed 57.1%. Yet shares remain 14.1% below the 52-week high of HKD 581 and trade well above MA20 (415.48) and MA60 (448.9); Goldman Sachs raised its TP to HKD 561.4 with a Buy rating. However, the company still reports negative EPS and a PB of 21.6x, while peer Akeso tumbled 8% today, weighing on sector sentiment.

  2. Jul, 2

    科伦博泰今日低开高走,上午盘从 465 港元开盘后一度冲高至 475.2 港元,下午盘小幅回落至 469.4 港元收盘,全天涨幅 7.6%,主要受 2026 年 ASCO 年会多项正面数据及与默沙东合作进展驱动。公司此前在 ASCO 口头报告了 sac-TMT 联合帕博利珠单抗一线治疗 PD-L1 阳性 NSCLC 的 III 期 OptiTROP-Lung05 研究,结果同步发表于《柳叶刀》;同时披露了 B7-H3 ADC SKB500 的首次人体数据及新一代 RET 抑制剂 A400(EP0031)的注册性 II 期数据。财务方面,2025 年 Q4 营业收入同比大增 110.38% 至 6.16 亿港元,净亏损同比收窄 57.1% 至 1.32 亿港元,亏损幅度持续改善。当前股价 469.4 港元距 52 周高点 581 港元仍低 19.21%,但已站上 MA20(410.56 港元)和 MA60(448.9 港元),YTD 涨幅 17.17%。不过,在 ASCO 数据公布后股价曾出现 14.8% 的下跌,市场对已定价的催化剂存在获利回吐压力。

News

Bullish vs. Bearish — Last 3 Months

2.3k followers · 0 opinions
▲Bullish50%
50%Bearish▼